To investigate the therapeutic effect of Qingre Jieyu Decoction (清热解瘀汤) on the patients with thyroid nodules after ablation.

A hundred patients with thyroid nodules undergoing radiofrequency ablation treated in Guangdong Province Traditional Chinese Medical Hospital from June 2021 to June 2023 were included as the study objects, and were divided into two groups by the random number table method. Fifty patients in the control group were treated with conventional western medicine after radiofrequency ablation, and those in the observation group were treated with Qingre Jieyu Decoction after radiofrequency ablation. The therapeutic effects, symptom scores, maximum diameters and volumes of thyroid nodule, thyroid function indexes and so on of the two groups were compared.

After treatment, the total effective rate of the observation group was 96.0%, which was much higher than that of the control group (78.0%), and the scores of pain, swallowing discomfort, swelling and thermal swelling in the observation group were lower than those in the control group (P<0.05). After treatment, the nodule maximum diameter and nodule volume in the observation group were smaller than those in the control group, and the levels of serum thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) after treatment were better than those in the control group (P<0.05).

The application of Qingre Jieyu Decoction after radiofrequency ablation for the patients with thyroid nodules can relieve heat and toxin, eliminate abscess and desiccation, effectively improve swallowing discomfort, swelling, pain and other symptoms of the patients after surgery, promote the reduction of thyroid nodules, improve the thyroid function and promote postoperative recovery as soon as possible.

To investigate the effects of Ginkgo biloba extract on the inflammatory response in the rats with ulcerative colitis (UC) based on the Toll-like receptor 4 (TLR4) /nuclear factor-κB (NF-κB) signaling pathway.

Forty SD rats were divided model group, Ginkgo biloba extract low-dose group, Ginkgo biloba extract high-dose group and normal group, each with 10 rats. The levels of interleukin (IL) -1 β, IL-6 and tumor necrosis factor (TNF) -α were measured using the Enzyme linked immunosorbent assay (ELISA) method. The expressions of TLR4 and NF-κB proteins in colon tissue was assessed via Western blot (WB). The Disease Activity Index (DAI), colon length, colon mucosal damage index (CMDI), inflammatory factors, TLR4 and NF-κB protein expressions were compared among the groups.

The DAI score, colon mucosal damage index (CMDI) score, the protein gray values of IL-1β, IL-6, TNF-α, TLR4 and NF-κB in the model group, Ginkgo biloba extract low-dose group and Ginkgo biloba extract high-dose group were higher than those of the normal group, while the colon length was shorter than that of the normal group (P<0.05). The DAI score, CMDI score, the protein gray values of IL-1β, IL-6,TNF-α, TLR4 and NF-κB of the Ginkgo biloba extract low-dose and high-dose groups were lower than those of the model group, while the colon length was longer than that of the model group (P<0.05). The DAI score, CMDI score, the protein gray values of IL-1β, IL-6, TNF-α, TLR4 and NF-κB of the Ginkgo biloba extract high-dose group were lower than those of the Ginkgo biloba extract low-dose group, while the colon length was longer than that of the low-dose Ginkgo biloba extract group (P<0.05).

Ginkgo biloba extract can alleviate the inflammatory response in the UC rats, and its mechanism may be related to the regulation of TLR4/NF-κB signaling pathway expression.

To investigate the clinical effect of Modified Longdan Xiegan Decoction (龙胆泻肝汤加减) combined with hepatic artery chemoembolization in the treatment of primary liver cancer complicated with portal vein cancer thrombus.

A total of 64 patients with primary liver cancer complicated with portal vein cancer thrombus admitted from January 2020 to January 2023 were included in the study and divided into into chemoembolization group (32 cases) and combined Chinese medicine group (32 cases) by random number table method. The patients in the chemoembolization group were treated with hepatic artery chemoembolization. Those in the combined Chinese medicine group were treated with Longdan Xiegan Decoction combined with hepatic artery chemoembolization, and the data of the patients in each group was observed, including the clinical efficacy, the changes in the total scores of TCM symptoms and the changes in the quality of life (QOL) before and after treatment, Eastern Cooperative Oncology Group (ECOG) scores, the changes of tumor markers such as Alpha-Feto protein (AFP), carcinoembryonic antigen (CEA), immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM), adverse reactions and 1-year survival rate.

The total effective rate of the combined Chinese medicine group was higher than that of the chemoembolization group (P<0.05). The total TCM syndrome scores, QOL score, ECOG score, tumor markers (AFP and CEA), immune function indexes (IgA, IgG, IgM) and other indexes were not significant between the two groups before treatment (P>0.05). After treatment, the total TCM syndrome scores, QOL score, ECOG score, tumor markers (AFP and CEA), immune function indexes (IgA, IgG, IgM) and other indexes were improved in both groups. These indexes in the combined Chinese medicine group were better than those in the chemoembolization group (P<0.05). The incidence of gastrointestinal discomfort and alopecia in the combined Chinese medicine group was lower than that in the chemoembolization group (P<0.05). The 1-year survival rate in the combined Chinese medicine group was higher than that in the chemoembolization group (P<0.05).

Modified Longdan Xiegan Decoction combined with hepatic artery chemoembolization has good clinical effect in the treatment of primary liver cancer complicated with portal vein cancer embolus, which can improve the patients'quality of life, immune ability and physical condition, reduce the rate of chemotherapy adverse reactions to a certain extent, and improve the 1-year survival rate of the patients.

To analyze the clinical effect of Qishen Yiqi Dripping Pill (芪参益气滴丸) combined with dapagliflozin and sacubitril-valsartan in the treatment of chronic heart failure.

A total of 206 patients with chronic heart failure with reduced ejection fraction who were admitted to Qinghai Special Hospital of Cardio-cerebrovascular Disease from June 2021 to June 2023 were selected and divided into control group (103 cases) and observation group (103 cases) by random number table method. The control group was treated with dapagliflozin and sacubitril-valsartan, and the observation group was treated with Qishen Yiqi Dripping Pill on the basis of the control group, and both groups were treated continuously for 8 weeks. The TCM syndrome scores, cardiac function index, serological index, 6 min walking test distance, quality of life, clinical efficacy and adverse reactions of the two groups were observed before and after treatment.

After 8 weeks of treatment, the TCM syndrome scores, the levels of left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), hypersensitive C-reactive protein (hs-CRP), amino terminal brain natriuretic peptide precursor (NT-proBNP) and Minnesota Living with Heart Failure Quality of Life Questionnaire (MLHFQ) in the observation group were lower than those of the control group (P<0.05), and the levels of left ventricular ejection fraction (LVEF), cardiac output (CO) and left ventricular ejection fraction (LVEF) and 6 min walking test distance were lower than those of the control group (P<0.05). The total effective rate in the observation group was higher than that of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

The combination of Qishen Yiqi Dripping Pill and dapagliflozin and sacubitril-valsartan in the treatment of chronic heart failure can effectively alleviate the clinical symptoms, improve the cardiac function, reduce the inflammatory response and the risk of cardiac remodeling, enhance the cardiac reserve, increase the exercise tolerance and improve the quality of life of the patients, with clear efficacy and high safety.

To observe the clinical efficacy of acupuncture in the treatment of anorexia nervosa with cancer by regulating Du meridian and strengthening spleen, and to explore the mechanism of its action.

The cases were included from October 2022 to June 2024, and 80 patients with anorexia nervosa with carcinoma attending the Department of Medical Oncology of the hospital were divided into the conventional group and the acupuncture group, each with 40 cases, using the random number table method. The conventional group was treated with conventional treatment of tumor, and the acupuncture group was treated with the acupuncture method of regulating Du meridian and strengthening spleen on the basis of the conventional treatment of tumor, and was treated continuously for 6 weeks. Body mass, quantitative appetite scale (NRS) scores, functional assessment of anorexia/malassemia treatment (FAACT) scores and traditional Chinese medicine syndrome scores and the levels of tumour necrosis factor-alpha (TNF-α), haemoglobin, albumin, interleukin-6 (IL-6), orexin A and leptin were compared between the two groups before and after treatment for 3 and 6 weeks and the clinical effect was evaluated.

Before treatment, the differences in body mass, NRS scores, traditional Chinese medicine syndrome scores and FAACT scores were not statistically significant between two groups (P>0.05). Comparing 3 and 6 weeks of treatment with the pre-treatment period, the body mass and FAACT scores of the two groups increased, and the traditional Chinese medicine syndrome scores and NRS scores decreased (P<0.05). Comparing 3 and 6 weeks of treatment, the two groups had higher body mass and FAACT scores and lower traditional Chinese medicine syndrome scores and NRS scores than the conventional group (P<0.05). The differences in haemoglobin, albumin, TNF-α, IL-6, orexigenin A and leptin were not statistically significant between the two groups compared with those before treatment (P>0.05). Comparing 3 and 6 weeks of treatment with pre-treatment, the levels of haemoglobin, orexin A, albumin increased and TNF-α, IL-6 and leptin decreased in both groups (P<0.05) and those levels in the acupuncture group were significantly lower compared with those in the conventional group (P<0.05). The total effective rate of the acupuncture group (87.50%) was higher than that of the conventional group (67.50%), and the difference was statistically significant (P<0.05).

Acupuncture treatment of cancerous anorexia nervosa with the method of regulating Du meridian and strengthening spleen improves the nutritional status of the body and enhances the therapeutic efficacy, which may be related to the regulation of the neuro-endocrine network.

To explore the effect of Shugan Huayu Jieyu Decoction (疏肝化瘀解郁汤) combined with acupuncture on post-stroke depression and its influence on patients'physical and mental health.

A total of 119 patients with post-stroke depression admitted to the hospital from December 2020 to November 2023 were divided into groups by random number table method, and the patients were divided into western medicine group (59 cases) and traditional Chinese medicine group (60 cases). The patients in the western medicine group were treated with fluoxetine hydrochloride, and those in the traditional Chinese medicine group were treated with Shugan Huayu Jieyu Decoction combined with acupuncture therapy. The clinical efficacy and adverse reactions, traditional Chinese medicine symptom scores (depression, loss of interest, irritability, slow thinking, insomnia, fatigue, etc.) before and after treatment, Hamilton depression scale (HAMD) score and National Institute of Health stroke scale (NIHSS) score, the levels of norepinephrine (NE) and 5-hydroxytryptophan (5-HT), Pittsburgh sleep quality index (PSQI) and activities of daily living (ADL) scores of two groups were compared.

The total effective rate of traditional Chinese medicine group was 96.67%, which was higher than that of western medicine group (86.44%) (P<0.05). The adverse reaction rates of traditional Chinese medicine group and western medicine group were 3.33% and 3.39%, respectively, which were more tolerable by patients (P>0.05). Before treatment, traditional Chinese medicine syndrome scores (depression, loss of interest, irritability, slow thinking, insomnia, fatigue, etc.), HAMD score, NIHSS score, the levels of NE and 5-HT, PSQI score and ADL score were not significant in two groups (P>0.05). After treatment, traditional Chinese medicine syndrome scores (depression, loss of interest, irritability, slow thinking, insomnia, fatigue, etc.), HAMD scores, NIHSS scores, the levels of NE and 5-HT, PSQI scores and ADL scores were improved in two groups. After treatment, these indexes in traditional Chinese medicine group were all better than those in western medicine group (P<0.05).

The combination of Shugan Huayu Jieyu Decoction and acupuncture in the treatment of post-stroke depression is significant, safe and reliable.

To investigate the clinical effect of Modified Sijunzi Decoction (四君子汤加减) combined with FOLFOX4 in the treatment of primary gastric cancer.

A total of 98 patients with primary gastric cancer admitted from January 2021 to April 2024 were included in the study and divided into FOLFOX4 regimen group and combined Chinese medicine group by random number table method. All patients in FOLFOX4 regimen group (49 cases) were treated with FOLFOX4 chemotherapy regimen. The patients in the combined Chinese medicine group (49 cases) were treated with Sijunzi Decoction combined with FOLFOX4 regimen. The data of each group was compared, including the clinical efficacy, stomach intake or poor appetite, abnormal stool, lack of thirst, continuous abdominal pain or warm preference, intestinal distress and other traditional Chinese medicine syndrome score changes, the levels of gastrin (GAS), pepsinogen Ⅰ (PGⅠ) and pepsinogen Ⅱ (PGⅡ), the levels of gastrointestinal hormone, carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA), changes in T cell subsets such as CD3⁺, CD4⁺, CD8⁺ and adverse reactions to chemotherapy.

The total effective rate of the combined Chinese medicine group was higher than that of FOLFOX4 regimen group (P<0.05). Before treatment, the two groups of patients with decreased stomach intake or poor appetite, abnormal stool, lack of thirst, continuous abdominal pain or traditional Chinese medicine syndrome scores, gastrointestinal hormone levels (GAS, PGⅠ, PGⅡ), tumor marker levels (CA125, CEA), CD3⁺, CD4⁺, CD8⁺ and other indicators were not significant (all P>0.05). After treatment, the combined Chinese medicine group were better than those in the FOLFOX4 group in terms of reduced stomach intake, poor appetite, abnormal stool, lack of thirst, continuous abdominal pain, warm preference, colon distress, gastrointestinal hormone level (GAS, PGⅠ, PGⅡ), tumor marker levels (CA125, CEA), CD3⁺, CD4⁺, CD8⁺ and other indicators (P<0.05). The incidence of gastrointestinal discomfort in the combined Chinese medicine group was lower than that in the FOLFOX4 regimen group (P<0.05).

Sijunzi Decoction combined with FOL-FOX4 has good clinical effect in the treatment of primary gastric cancer, which can effectively reduce the levels of tumor markers, improve the disease and gastrointestinal hormone levels, improve the immune function of patients and reduce some adverse reactions, and the treatment is safe and reliable.